The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus is causing a
global pandemic, and cases continue to rise. Most infected individuals experience mildly …

The development of a portfolio of COVID-19 vaccines to vaccinate the global population
remains an urgent public health imperative 1 . Here we demonstrate the capacity of a subunit …

Most individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
develop neutralizing antibodies that target the viral spike protein. In this study, we …

A safe, effective, and scalable vaccine is needed to halt the ongoing SARS-CoV-2 pandemic.
We describe the structure-based design of self-assembling protein nanoparticle …

Understanding vaccine-elicited protection against SARS-CoV-2 variants and other
sarbecoviruses is key for guiding public health policies. We show that a clinical stage multivalent …

Despite the remarkable efficacy of COVID-19 vaccines, waning immunity and the emergence
of SARS-CoV-2 variants such as Omicron represents a global health challenge. Here, we …

Nanoparticles for multivalent display and delivery of vaccine antigens have emerged as a
promising avenue for enhancing B cell responses to protein subunit vaccines. Here, we …

Adjuvants enhance the magnitude and the durability of the immune response to vaccines.
However, there is a paucity of comparative studies on the nature of the immune responses …

microRNA ( miRNA ) and RNA ‐binding proteins ( RBPs ) have been studied widely in post‐transcriptional
gene regulation. Previous work has focused on defining how miRNA and …

Protein nanoparticle scaffolds are increasingly used in next-generation vaccine designs,
and several have established records of clinical safety and efficacy. Yet the rules for how …